(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 13.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Xencor's revenue in 2026 is $97,360,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $5,823,970,649, with the lowest XNCR revenue forecast at $1,017,222,697, and the highest XNCR revenue forecast at $13,178,668,689. On average, 16 Wall Street analysts forecast XNCR's revenue for 2027 to be $8,729,431,513, with the lowest XNCR revenue forecast at $1,089,881,461, and the highest XNCR revenue forecast at $30,288,324,798.
In 2028, XNCR is forecast to generate $10,111,430,862 in revenue, with the lowest revenue forecast at $4,219,324,087 and the highest revenue forecast at $26,352,147,466.